UK markets closed

Kiromic BioPharma, Inc. (KRBP)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.18600.0000 (0.00%)
As of 03:48PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 234.07k
Enterprise value 7.20M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)11.55
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.37

Trading information

Stock price history

Beta (5Y monthly) 0.68
52-week change 3-97.30%
S&P500 52-week change 314.78%
52-week high 39.3000
52-week low 30.1600
50-day moving average 30.2632
200-day moving average 32.4592

Share statistics

Avg vol (3-month) 38.52k
Avg vol (10-day) 32.5k
Shares outstanding 51.26M
Implied shares outstanding 61.26M
Float 8572.94k
% held by insiders 13.91%
% held by institutions 168.50%
Shares short (30 Aug 2023) 445.74k
Short ratio (30 Aug 2023) 41.45
Short % of float (30 Aug 2023) 46.82%
Short % of shares outstanding (30 Aug 2023) 43.89%
Shares short (prior month 30 Jul 2023) 462.44k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:30
Last split date 312 Mar 2023

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-98.81%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -19.32M
Net income avi to common (ttm)-24.99M
Diluted EPS (ttm)-19.5100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)4.38M
Total cash per share (mrq)3.48
Total debt (mrq)11.35M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.34
Book value per share (mrq)-3.82

Cash flow statement

Operating cash flow (ttm)-19.92M
Levered free cash flow (ttm)-14.6M